Most effective hepatitis C treatment fails in majority of Hispanics, study shows

Jan 15, 2009 By Bob LaMendola

The most effective treatment for hepatitis C fails in two-thirds of Hispanic patients but works for half of white patients, researchers reported Wednesday in a study that confirms ethnic disparities in the liver disease.

The study follows earlier research showing that the drug combination used to treat the hepatitis C virus also fails for almost three-quarters of black patients. Doctors said unknown biological differences may diminish the success of the drugs in minority patients.

"There may be factors in individuals, in their immune response, that may be related to their ethnicity," said Dr. Paul Martin, senior author of the study and chief of liver diseases at the University of Miami medical school.

Doctors and hepatitis advocates said patients should not give up on the drugs. The combination - pegylated interferon plus ribavirin - is a step up from a decade ago, when drugs worked in only 10 percent. New and better drugs are in the works.

Hepatitis C is a leading cause of liver cancer and cirrhosis, and fueled a jump in liver transplants. The virus spreads in blood, mainly via injection drug use and transfusions before 1992.

About 4 million nationally have chronic hepatitis C. A blood test can detect the virus, and the drug combination can eradicate it - when it works.

The new study in the New England Journal of Medicine gave the drugs to 269 Hispanic patients and 300 white patients for a year. They were deemed a success if they were virus-free six months after that.

The drugs worked for 49 percent of white patients but only 34 percent of Hispanic patients. The Hispanics never got rid of the virus, or it returned.

"It's probably genetic or biology," said Dr. Lennox Jeffers, chief of liver disease at the Veterans Affairs Medical Center in Miami, who worked on this study and two with black patients.

___

FOR MORE INFORMATION

To read the study:
content.nejm.org/

For more information:
www.cdc.gov/hepatitis/
or call 800-232-4636.

___

© 2009, Sun Sentinel.
Visit the Sun-Sentinel on the World Wide Web at www.SunSentinel.com
Distributed by McClatchy-Tribune Information Services.

Explore further: Scientists identify a new variant of Ebola virus in Guinea

add to favorites email to friend print save as pdf

Related Stories

The promise and peril of nanotechnology

Mar 26, 2014

Scientists at Northwestern University have found a way to detect metastatic breast cancer by arranging strands of DNA into spherical shapes and using them to cover a tiny particle of gold, creating a "nano-flare" ...

Aging ISS a space lab of 'unlimited' opportunity

Jan 27, 2014

It may be 350 kilometers (215 miles) above Earth and a place that only a privileged few will ever visit, but the International Space Station is crucial to advances in science, health and technology, experts ...

Adult stem cells found to suppress cancer while dormant

Dec 20, 2013

Researchers at UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have discovered a mechanism by which certain adult stem cells suppress their ability to initiate skin cancer during their dormant ...

Recommended for you

Impact of whooping cough vaccination revealed

6 hours ago

The most comprehensive study to date of the family of bacteria that causes whooping cough points to more effective vaccine strategies and reveals surprising findings about the bacteria's origin and evolution. The new results ...

User comments : 0

More news stories

Cyber buddy is better than 'no buddy'

A Michigan State University researcher is looking to give exercise enthusiasts the extra nudge they need during a workout, and her latest research shows that a cyber buddy can help.

Man among first in US to get 'bionic eye' (Update)

A degenerative eye disease slowly robbed Roger Pontz of his vision. Diagnosed with retinitis pigmentosa as a teenager, Pontz has been almost completely blind for years. Now, thanks to a high-tech procedure ...